U.S. Markets closed

Portola Pharmaceuticals to Present at the Credit Suisse 26th Annual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (PTLA) today announced that Bill Lis, chief executive officer, will present at the Credit Suisse 26th Annual Healthcare Conference on Wednesday, November 8, at 8:40 a.m. Mountain Time in Scottsdale, AZ.

The presentation will be webcast live and available for replay for 30 days following the presentation on the Credit Suisse website.

About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company’s first medicine Bevyxxa® (betrixaban), an oral, once-daily Factor Xa inhibitor, was approved by the U.S. Food and Drug Administration in June 2017. The company is also working to advance two clinical programs for AndexXa® (andexanet alfa), a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a SYK/JAK inhibitor in development to treat hematologic cancers. Portola's partnered program is focused on developing selective SYK inhibitors for inflammatory conditions. For more information, visit http://www.portola.com and follow the Company on Twitter @Portola_Pharma.

     
Investor Contact:   Media Contact:
Michele Mantynen   Patrick Ryan
Portola Pharmaceuticals   W2O Group
ir@portola.com    pryan@w2ogroup.com